CEL-SCI files patent for avian bird flu drug CEL-1000

By Elaine Rigoli

Tampa, Fla., April 4 - CEL-SCI Corp. has filed a provisional U.S. patent application covering its drug CEL-1000 for the prevention/treatment of bird flu and/or as an adjuvant to be included in a bird flu vaccine.

CEL-1000, when used as a single enhancer of a vaccine or in combination, potentiates Th1 (cellular) and earliest-stage immune responses and protects animals from viral and parasitic challenge, according to a news release.

CEL-1000 provides antigen-independent (i.e., non-disease specific) and broad-spectrum protection upon challenge with the disease causing agents, which is important against the bird flu virus since it exhibits a high mutation rate.

CEL-1000 is a patented defined amino acid sequence derived from the beta chain of human MHC-2, which itself is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response, the release said.

It is a defined peptide, which binds to the CD4 and/or likely a related molecule LAG-3 on dendritic cells, macrophages and T cells, thereby promoting the release of cytokines responsible for activating a protective Th1 immune response.

CEL-SCI, developing new immune system-based treatments for cancer and infectious diseases, has operations in Vienna, Va. and Baltimore, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.